Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study

Daniel S.W. Tan, Sang‐We Kim, Santiago Ponce Aix, Lecia V. Sequist, Egbert F. Smit, James Chih‐Hsin Yang, Toyoaki Hida, Ryo Toyozawa, Enriqueta Felip, Juergen Wolf, Christian Grohé, Natasha B. Leighl, Gregory J. Riely, Xiaoming Cui, Mike Zou, Samson Ghebremariam, Leslie O’Sullivan-Djentuh, Riccardo Belli, Monica Giovannini, Dong‐Wan Kim